

Mainstay Medical CEO to Present at the BioTrinity European Biopartnering and Investment Conference in London

Dublin – Ireland, 8 May, 2015 – Mainstay Medical International plc (*Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE*) announces that its Chief Executive Officer, Peter Crosby, is scheduled to present at the BioTrinity European Biopartnering and Investment Conference at 15.20pm GMT on Wednesday, 13th May, 2015. The conference is being held at The Novotel London West, 1 Shortlands, London W6 8DR, England.

Mr. Crosby will be available for one-on-one meetings at this conference (investor-relations@mainstay-medical.com).

The associated corporate presentation for the Conference will be available on the Mainstay Medical website (www.mainstay-medical.com) from the time of commencement of Mr. Crosby's presentation for a maximum period of one month or until replaced by an updated corporate presentation.

- End -

About Mainstay

Mainstay is a medical device company which is developing an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). Low Back Pain is a leading cause of activity limitation and work absence throughout much of the developed world, imposing a high economic burden on individuals, families, communities, industry, and governments.

The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on economies.

Further information can be found at www.mainstay-medical.com

European queries:

Jonathan Neilan, FTI Consulting

Tel: +353 1 663 3686

Email: jonathan.neilan@fticonsulting.com

Astrid Villette, FTI Consulting (French language enquiries)

Tel: +33 1 47 03 69 51

Email: Astrid.Villette@fticonsulting.com

US queries:

Jillian Connell, The Trout Group LLC

Tel: +1 646 378 2956 / +1 617 309 8349

Email: jconnell@troutgroup.com

ESM Advisers:

Fergal Meegan or Barry Murphy, Davy

Tel: +353 1 679 6363

Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie